VerImmune
Bethesda, US · Founded 2019 · Delaware corporation · 4 known investors
VerImmune develops immunotherapy medicines that redirect pre-existing immune memory toward cancer cells to achieve tumor destruction with low toxicity. The company targets cancer patients across a broad range of cancer types.
BiotechHealthtechMedical Devices
Founders & leadership
VerImmune was founded in 2019 by JOSHUA WANG.
JW
JOSHUA WANGFounder
JT
JOHN TROYERNamed on SEC filing
Board
Investors · 4
__Twitter.png)
Reported raises · per SEC filings
Form D private placements$5.9M disclosed across 2 rounds · 2022–2024
▶$4.5MraisedSep 2024 · 6 investors · BiotechnologyRule 506(b)
▶$4.5MraisedSep 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CYNTHIA POHDirector
- KEVIN KOH RONGSHENGDirector
- HAOLIN SUNGDirector
- CHE HSUDirector
- MARTA NEWDirector
- JOSHUA WANGExecutive Officer, Director, Promoter
- ROGER POMERANTZDirector
- Offering amount
- $8M
- Amount sold
- $4.5M
- Minimum investment
- $22.8K
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.4MraisedMar 2022 · 9 investors · BiotechnologyRule 506(b)
▶$1.4MraisedMar 2022 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- ROGER POMERANTZDirector
- JOHN TROYERExecutive Officer
- CYNTHIA POHDirector
- JOSHUA WEIYUAN WANGExecutive Officer, Director, Promoter
- KEVIN KOH RONGSHENGDirector
- Offering amount
- $2.5M
- Amount sold
- $1.4M
- Minimum investment
- $25K
- Proceeds to insiders
- $125K
- First sale
- Mar 2022
- Incorporated
- Corporation, Maryland, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapInfinimmune18 shared keywordsInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
Inimmune17 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
Immuneering16 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Immunomic Therapeutics14 shared keywordsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
Companies competing with VerImmune for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does VerImmune do?
- VerImmune develops immunotherapy medicines that redirect pre-existing immune memory toward cancer cells to achieve tumor destruction with low toxicity. The company targets cancer patients across a broad range of cancer types.
- Who founded VerImmune?
- VerImmune was founded by JOSHUA WANG in 2019.
- Who are VerImmune's investors?
- VerImmune's investors include Maryland TEDCO, Ulu Ventures, Gaingels, Mana Ventures.
- How much funding has VerImmune raised?
- VerImmune has disclosed $5.9M raised across 2 rounds.
- Where is VerImmune headquartered?
- VerImmune is headquartered in Bethesda, US.